Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online


             
 

Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.

Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.

Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.

Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.

Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.



NAVIGATION


         

 

Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, announced plans for a tax-free spin-off of its clinical and medical products businesses as a separate public company that will be led by current vice chairman and med-tech industry veteran David L. Schlotterbeck.

 

Daily hemodialysis administered in patients’ homes is associated with better health outcomes compared with peritoneal dialysis, according to an article in the October issue of the American Journal of Kidney Diseases, the official journal of the National Kidney Foundation.

 

MIT biological engineers have found a way to mass-produce smell receptors in the laboratory, an advance that paves the way for “artificial noses” to be created and used in a variety of settings. The work could also allow scientists to unlock the mystery of how the sense of smell can recognize a seemingly infinite range of odors. “Smell is perhaps one of the oldest and most primitive senses, but nobody really understands how it works.

 

Data from ground-breaking scientific trials of new interventional techniques and devices will be released at TCT 2008 - Transcatheter Cardiovascular Therapeutics - the global annual scientific symposium of the Cardiovascular Research Foundation. Researchers will present a variety of new data that promises to advance the field of interventional cardiology.

 

OrthoView™, the global leader in orthopaedic planning solutions, today announced the release of its latest version 5.2 software. Building on its already feature-rich version 5.1, OrthoView 5.2 includes refinements and additions to its spine deformity assessment module.

 

Cambridge Research Biochemicals (CRB), a specialist in the custom production of polyclonal antibodies, is now expanding its antibody offering to include monoclonal antibody production via two new agreements with Babraham Bioscience Technologies (BBT) and Epitomics Inc. CRB and Cambridge-based BBT have formed an alliance that will enable CRB to market custom monoclonal antibody projects (via mouse/rat hybridomas) from BBT.

 

There are over four thousand wrist or ankle fractures every day in US and Europe. The cost is not just the medical treatment involved but the loss of quality of life. An improved way to treat the fractures has been developed by CAMBfix, a company started by Cambridge alumni. CAMBfix announced that it has received £65,000 funding from Cambridge Enterprise Seed Funds and matching funds of £65,000k from North East Equity Matching Limited. The

 

Ever since Darwin’s grandson set up Cambridge Instruments to supply the university with specialist glassware, the medical technology, devices and diagnostic industry has been a thriving part of the regional economy - but one that has been unfairly overshadowed by the biotech sector according to Barnaby Perks of ERBI Medtech. Barnaby joined ERBI in January to set up a section especially for organisations working in Medtech.

 

The first national guideline for the emergency use of oxygen in adults has been published, with the aim of simplifying oxygen delivery and better protecting acutely ill patients. Developed by a working party and led by the British Thoracic Society (BTS), the guideline is published in the October 2008 issue of Thorax1, the journal of the BTS, and is supported by 22 professional societies and institutions.

 

Randox Laboratories have developed a biochip array for simultaneous quantitative detection of three tumour markers in a single patient sample, providing a quick and reliable method to screen for prostate cancer. This revolutionary technology reduces the need for expensive invasive tests. Prostate cancer is the second most common cancer found in men but if caught and treated early has a 90% cure rate.




September 2008
Mon Tue Wed Thu Fri Sat Sun
« Aug   Oct »
1234567
891011121314
15161718192021
22232425262728
2930